[MUSIC]
I'm delighted to be part of this team and because it is the best in the world.
The achievements in head neck cancer care that
have occurred here in Johns Hopkins have been seminal.
And oh, many patients have benefited from the discoveries made here, and
the refinements in patient treatments that have been achieved here at Johns Hopkins.
>> I always tell my patients that I'm only as good as
the team around me, and the team around me is the best.
That is one of the things that, I think, that makes this place really special.
>> There's two nodules in here.
>> We just want to want to know if there's two nodules here.
>> We have a great team.
We have ten head, neck surgeons focused on head, neck cancer in our department.
The level of expertise is astounding.
>> Also a multidisciplinary team of experts in medical oncology.
Our chemotherapy and radiation oncology.
And our pathologist, our anesthesia team, our speak-language pathologist.
>> I'm gonna have you count from one to ten for me.
>> One, two, three.
>> Sounds
great.
>> We have a very active, multidisciplinary skull base group.
Skull-based cancer, in this case, is usually cancer in the paranasal sinuses.
>> We're gonna make an incision here and we.
>> Around the nose, up under the sinuses, and in the area behind the
eyes that requires often interaction between otolaryngologist.
Your nose and throat surgeons, and neurosurgeons.
So we have a group of surgeons that will work for 24 hours if they need to, to
remove a tumor in that very complex area where
the brain and the sinuses and facial tissues come together.
>> At the end of the procedure, you get
the, your final report that I have already performed.
>> And another thing that's exciting.
Is the training programs that we have to offer here at Johns Hopkins.
We're training future leaders in this area.
Individuals that will make significant
discoveries and progress against this disease.
That's real exciting.
We have a multidisciplinary Conference each week, during
which we discuss a specific case, and then delineate
the options, and then work with the patient to
tailor a treatment approach that is best for them.
This may involve a surgical approach or a non-surgical approach.
Robotic surgery, or endoscopic skull based surgery.
We have state of the art technology and high tech equipment and expertise.
>> These are [UNKNOWN].
>> Right, you know, it's a tiny.
>> The thing is our long track
record, 20 years or more, of clinical investigation.
In the laboratory that brings innovations to the bedside so that we're at the
cutting edge of, of understanding what makes cancer work and how to stop it.
>> Our program has been successful in delineating
why these tumors occur at the molecular level.
How HPV relates to oralpharyngeal cancer.
>> Early detection has one of our main areas of interest.
We're working on a test that will use advanced enocular
staging to find cancer cells in saliva and in blood samples.
We're also interested in targets.
For chemotherapy approach as what they call individualized medicine.
So if we know what alterations have occurred in one individual's
cancer then chemotherapy options specific to that change can be used.
>> Alright so, you're in good hands and he's up here.
>> Of course our first concern is to cure the cancer.
That's everyone's main concern when they come in.
But as they go through the treatment, and, look at, the hope of surviving for
many years afterwards, their ability to function day to day, rises to the floor.
So we need to support and want to support
them in their recovery after cancer therapy is finished.
>> The team is intensely focused on this challenging disease.
They wanna make progress.
They wanna see better outcome.
They wanna see cure.
[MUSIC]